Advertisement

Breast Cancer Research and Treatment

, Volume 171, Issue 1, pp 225–234 | Cite as

Effect of glucocorticoid use on survival in patients with stage I–III breast cancer

  • Ching-Hung Lin
  • Po-Ya Chuang
  • San-Lin You
  • Chun-Ju Chiang
  • Chiun-Sheng Huang
  • Ming-Yang Wang
  • Ming Chao
  • Yen-Shen Lu
  • Ann-Lii Cheng
  • Chao-Hsiun Tang
Epidemiology

Abstract

Purpose

Glucocorticoids (GCs) are commonly used in breast cancer patients to ameliorate emesis induced by chemotherapy. Some preclinical studies have suggested that systemic GCs might promote survival of estrogen receptor (ER)-negative breast cancer cells. This study aims to clarify their clinical effect on patient survival.

Methods

A total of 18,596 women with newly diagnosed stage I–III breast cancer in 2002–2006 were identified from the Taiwan Cancer Database and drug treatment was examined from the Taiwan National Health Insurance Claims Database. Of these, 3989 who did not receive adjuvant chemotherapy (non-chemotherapy cohort) and 3237 patients who received six cycles of adjuvant anthracycline-based chemotherapy (anthracycline cohort) were included. The impact of GC use on survival was analyzed separately in these two cohorts using Cox proportional hazards models.

Results

In the non-chemotherapy cohort, GC use was associated with aggressive clinicopathological features of breast cancer. High-dose GC was associated with shorter overall survival in univariate analysis but not in multivariate analysis. In the anthracycline cohort, multivariate analysis showed that GC use at each dose level was significantly associated with longer breast cancer-specific survival (HR 0.65, 0.70, and 0.70 for low-dose, median-dose, and high-dose GC, respectively) and overall survival (HR 0.72, 0.76, and 0.73, respectively) when compared with those receiving no GC. The associations were significant in both ER-positive and ER-negative subgroups for breast cancer-specific survival, and in ER-negative subgroup for overall survival.

Conclusion

Concomitant use of GC improved survival in patients receiving adjuvant anthracycline-based chemotherapy for stage I–III breast cancer.

Keywords

Glucocorticoid Breast cancer Adjuvant chemotherapy Survival 

Notes

Acknowledgements

This study was supported by grants from the National Science Council, Taiwan (Grant NSC 99-2410-H-038-004); the National Center of Excellence for Clinical Trial and Research, Taiwan (Grant Number MOHW105-TDU-B-211-134005); and the Ministry of Science and Technology, ROC. (MOST 105-2911-I-002-302). The funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, writing assistance, or decision to submit results.

Compliance with ethical standards

Conflict of interest

No potential conflicts of interest exist.

Supplementary material

10549_2018_4787_MOESM1_ESM.docx (44 kb)
Supplementary material 1 (DOCX 44 kb)

References

  1. 1.
    Rutz HP (2002) Effects of corticosteroid use on treatment of solid tumours. Lancet 360:1969–1970CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang C, Beckermann B, Kallifatidis G et al (2006) Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol 29:1295–1301PubMedGoogle Scholar
  3. 3.
    Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT (1993) Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133:521–528CrossRefPubMedGoogle Scholar
  4. 4.
    Biswas T, Ramana CV, Srinivasan G et al (1999) Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 18:525–532CrossRefPubMedGoogle Scholar
  5. 5.
    Naumann U, Durka S, Weller M (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17:1567–1575CrossRefPubMedGoogle Scholar
  6. 6.
    Wu W, Chaudhuri S, Brickley DR et al (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64:1757–1764CrossRefPubMedGoogle Scholar
  7. 7.
    de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37CrossRefPubMedGoogle Scholar
  8. 8.
    Herr I, Marme A (2005) Glucocorticoids and progression of breast cancer. Cancer Biol Ther 4:1415–1416CrossRefPubMedGoogle Scholar
  9. 9.
    Schmidt S, Rainer J, Ploner C et al (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11(Suppl 1):S45–S55CrossRefPubMedGoogle Scholar
  10. 10.
    Keith BD (2008) Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 8:84CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Jakobsen A, Frederiksen PL, Moller KA et al (1986) Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22:1067–1072CrossRefPubMedGoogle Scholar
  12. 12.
    Mercer PM, Ebbs SR, Fraser SC et al (1993) Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 19:254–258PubMedGoogle Scholar
  13. 13.
    Stewart JF, Rubens RD, King RJ et al (1982) Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur J Cancer Clin Oncol 18:1307–1314CrossRefPubMedGoogle Scholar
  14. 14.
    Ingle JN, Mailliard JA, Schaid DJ et al (1991) A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 68:34–39CrossRefPubMedGoogle Scholar
  15. 15.
    Cocconi G, Bisagni G, Ceci G et al (1992) Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 10:984–989CrossRefPubMedGoogle Scholar
  16. 16.
    Rubens RD, Tinson CL, Coleman RE et al (1988) Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 58:626–630CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tormey DC, Gray R, Gilchrist K et al (1990) Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer 65:200–206CrossRefPubMedGoogle Scholar
  18. 18.
    Marini G, Murray S, Goldhirsch A et al (1996) The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol 7:245–250CrossRefPubMedGoogle Scholar
  19. 19.
    Lippman M, Bolan G, Huff K (1976) The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4602–4609PubMedGoogle Scholar
  20. 20.
    Goya L, Maiyar AC, Ge Y, Firestone GL (1993) Glucocorticoids induce a G1/G0 cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol Endocrinol 7:1121–1132PubMedGoogle Scholar
  21. 21.
    Hundertmark S, Buhler H, Rudolf M et al (1997) Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. J Endocrinol 155:171–180CrossRefPubMedGoogle Scholar
  22. 22.
    Mikosz CA, Brickley DR, Sharkey MS et al (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276:16649–16654CrossRefPubMedGoogle Scholar
  23. 23.
    Wu W, Pew T, Zou M et al (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280:4117–4124CrossRefPubMedGoogle Scholar
  24. 24.
    Chen Z, Lan X, Wu D et al (2015) Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. Nat Commun 6:8323CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lin CH, Chuang PY, Chiang CJ et al (2014) Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist 19:583–591CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wu CY, Chen YJ, Ho HJ et al (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906–1914CrossRefPubMedGoogle Scholar
  27. 27.
    Hu C (1999) Steroid equivalence converter. http://www.medcalc.com/steroid.html
  28. 28.
    Pan D, Kocherginsky M, Conzen SD (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71:6360–6370CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    DiMartino L, Demontis B, Mitchell IP et al (1991) A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mastectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report. Anticancer Res 11:869–872PubMedGoogle Scholar
  30. 30.
    Fentiman IS, Howell A, Hamed H et al (1994) A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. Br J Cancer 70:729–731CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lietzen LW, Ahern T, Christiansen P et al (2014) Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study. Ann Oncol 25:2419–2425CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kawamura A, Tamaki N, Kokunai T (1998) Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Neurol Med Chir 38:633–638 (Discussion 638–640) CrossRefGoogle Scholar
  33. 33.
    Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72CrossRefPubMedGoogle Scholar
  34. 34.
    Galluzzi L, Buque A, Kepp O et al (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17:97–111CrossRefPubMedGoogle Scholar
  35. 35.
    Casares N, Pequignot MO, Tesniere A et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61CrossRefPubMedGoogle Scholar
  37. 37.
    Schiavoni G, Sistigu A, Valentini M et al (2011) Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 71:768–778CrossRefPubMedGoogle Scholar
  38. 38.
    Cook AM, McDonnell AM, Lake RA, Nowak AK (2016) Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology 5:e1066062CrossRefPubMedGoogle Scholar
  39. 39.
    Ladoire S, Mignot G, Dabakuyo S et al (2011) In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224:389–400CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ching-Hung Lin
    • 1
    • 2
    • 3
  • Po-Ya Chuang
    • 4
  • San-Lin You
    • 5
    • 6
    • 7
  • Chun-Ju Chiang
    • 8
  • Chiun-Sheng Huang
    • 9
  • Ming-Yang Wang
    • 9
  • Ming Chao
    • 10
  • Yen-Shen Lu
    • 1
    • 2
  • Ann-Lii Cheng
    • 1
    • 2
    • 11
  • Chao-Hsiun Tang
    • 4
  1. 1.Department of OncologyNational Taiwan University HospitalTaipeiTaiwan
  2. 2.Department of Internal MedicineNational Taiwan University HospitalTaipeiTaiwan
  3. 3.Oncology CenterNational Taiwan University Hospital Hsin-Chu BranchHsin-ChuTaiwan
  4. 4.School of Health Care AdministrationTaipei Medical UniversityTaipeiTaiwan
  5. 5.Department of Public Health, College of MedicineNational Taiwan UniversityTaipeiTaiwan
  6. 6.Big Data Research CentreFu-Jen Catholic UniversityNew Taipei CityTaiwan
  7. 7.Genomics Research Center, Academia SinicaTaipeiTaiwan
  8. 8.Taiwan Cancer Registry and Graduate Institute of Epidemiology and Preventive Medicine, College of Public HealthNational Taiwan UniversityTaipeiTaiwan
  9. 9.Department of SurgeryNational Taiwan University HospitalTaipeiTaiwan
  10. 10.Department of SurgeryNational Taiwan University Hospital Hsin-Chu BranchHsin-ChuTaiwan
  11. 11.Graduate Institute of Oncology, College of MedicineNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations